Transforming cancer therapeutics

Aucentra Therapeutics is an Australian clinical-stage oncology biopharma company with integrated R&D and clinical capabilities

Established in 2017, Aucentra Therapeutics develops breakthrough drugs to address unmet medical needs in some of the most challenging cancers. Our novel compounds aim to transform cancer treatment by providing targeted and effective therapies with the potential for fewer side effects. Aucentra’s extensive pipeline of proprietary anti-cancer drugs include candidates for the treatment of leukaemia, glioblastoma, and colorectal, pancreatic, ovarian, breast and lung cancers. Our expertise in drug development, manufacturing and clinical trials facilitates the efficient progression of drug candidates from discovery through clinical development, with the ultimate goal of brining innovative treatments to patients.

A PIPELINE OF ORAL DRUG CANDIDATES

Our pipeline consists of first-in-class or best-in-class novel kinase inhibitors in pre-clinical and clinical stage development.

In particular, we focus on targeting cyclin-dependent kinases (CDKs), whose activity is frequently dysregulated in cancer cells. We develop highly selective small-molecule inhibitors designed to improve treatment efficacy and tolerability compared with existing therapies, particularly for cancers with significant unmet medical needs and limited treatment options.

UNIQUE DISCOVERY CAPABILITIES

We specialise in small-molecule drug discovery and development, with expertise spanning medicinal and pharmaceutical chemistry, cell-based and enzymatic assays, in vivo pharmacokinetics and efficacy studies, as well as translational research, biomarker development and clinical trials.

PARTNERING FOR SUCCESS

We complement our in-house expertise through strategic global partnerships to accelerate the discovery, development and clinical advancement of our innovative therapies. Strategic collaborations and investment are integral to our continued growth and success.

CONTACT

If you’d like to learn more about Aucentra, please send us an email.

 

  • This field is for validation purposes and should be left unchanged.

© 2026 AUCENTRA (ABN 48 623 009 861)

All rights reserved.

Lab image photography by Chris Oaten.